Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
On April 14, 2026, Ribo Life Science announced that the company's self-developed, world's first siRNA drug Vortosiran (RBD4059) targeting coagulation factor XI (FXI) has successfully submitted a Phase IIb clinical trial application (CTA) for stroke prevention in atrial fibrillation (SPAF) patients. This marks a milestone breakthrough in the global clinical development of small nucleic acid (siRNA) drugs in the field of anticoagulant therapy.Vortosiran achieves precise and long-lasting inhibition of FXI, intervening in the FXI-mediated coagulation pathway. While providing highly effective protection against thromboembolism, it significantly reduces the risk of bleeding. Compared with existing anticoagulation therapies, Vortosiran enhances clinical benefits for patients while lowering the risk of bleeding.Ribo Life Science has planned to conduct multiple IIb clinical trials covering thrombosis and cardiovascular indications. The clinical trial with the code name ORBIT-XI-AF, which is part of this submission, is one of them. Following the completion of the Phase IIa trial of Vortosiran for Coronary Artery Disease (CAD), this submission will further consolidate and strengthen the product's position as the fastest FXI globally.Leadership in Targeted Small Nucleic Acid Drugs.Chief Medical Officer of Ribo Life ScienceDr. Anders Gabrielsen: "The successful submission of this clinical trial application marks a significant breakthrough for Ribo Life Science and patients worldwide who lack optimal anticoagulation treatment options. As pioneers in the field of FXI-targeted siRNA therapy, we are accelerating the clinical development of Vortosiran to address the substantial unmet medical needs in stroke prevention for atrial fibrillation patients. This milestone fully demonstrates the strength of the company's siRNA technology platform and further solidifies our leading position in the next-generation anticoagulation therapy field."Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science, 6938.HK) is a global biopharmaceutical company dedicated to the development and commercialization of small interfering RNA (siRNA) drugs. Powered by its self-innovated small nucleic acid technology platform, the company has established a rich and differentiated product pipeline focusing on major disease areas such as cardiometabolic disorders, liver, and kidney diseases. Ribo Life Science is committed to providing revolutionary treatment solutions for patients worldwide through continuous innovation.Source: Ribo Life Science
Mastering CAR-T Therapy, Stem Cell Therapy, and GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
